Hwang et al. reported that a DPP-4 inhibitor alleviated hepatic steatosis and insulin resistance by increasing AMP-activated protein kinase (AMPK) phosphorylation and by inhibiting leukocyte cell-derived chemotaxin-2 expression [17]. Here, DPP4 is linked to fatty liver disease.